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Abstract
Background: Although new screening programmes with low‐dose computed tomog‐
raphy (LDCT) for lung cancer have been implemented throughout the United States, 
screening uptake remains low and screening‐eligible persons' decisions to screen or 
not remain poorly understood.
Objective: To describe how current and former long‐term smokers explain their deci‐
sions regarding participation in lung cancer screening.
Design: Phone interviews using a semi‐structured interview guide were conducted to ask 
screening‐eligible persons to describe their decisions regarding screening with LDCT. The 
interviews were transcribed and analysed with conventional content analytic techniques.
Setting and participants: A subsample of 40 participants (20 who had screened and 
20 who had not) were drawn from the sample of a survey study whose participants 
were recruited by Facebook targeted advertisements.
Results: The sample was divided into the following five groups based on their de‐
cisions regarding lung cancer screening participation: Group 1: no intention to be 
screened, Group 2: no deliberate consideration but somewhat open to being screened, 
Group 3: deliberate consideration but no definitive decision to be screened, Group 
4: intention to be screened and Group 5: had been screened. Reasons for screening 
participation decisions are described for each group. Across groups, data revealed 
that screening‐eligible persons have a number of misconceptions regarding LDCT, 
including that a scan is needed only if one is symptomatic or has not had a chest x‐ray. 
A physician recommendation was a key influence on decisions to screen.
Discussion and conclusions: Education initiatives aimed at providers and long‐term 
smokers regarding LDCT is needed. Quality patient/provider communication is most 
likely to improve screening rates.
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1  | INTRODUC TION
Lung cancer screening with annual low‐dose computed tomography 
(LDCT) is recommended by the U. S. Preventive Services Task Force 
(USPSTF) for long‐term current and former smokers.1 Lung cancer 
is the deadliest form of cancer; nearly 1.8 million people including 
154 050 Americans are expected to die from lung cancer in 2019.2,3 
Lung cancer kills more people in the United States than breast, col‐
orectal, pancreatic, and prostate cancers combined.4 Most die be‐
cause they are diagnosed at an advanced stage, and, until recently, 
an effective screening test did not exist.
LDCT of the chest is promising for the early detection of lung 
cancer. The National Lung Screening Trial (NLST), the largest ran‐
domized controlled trial to date on lung cancer screening, found 
an approximate 20% relative reduction in lung cancer‐related mor‐
tality in high‐risk individuals (age 55‐74, current or former smok‐
ers who have quit within the past 15 years, and have at least a 30 
pack‐year history of cigarette smoking) screened with annual LDCT 
compared to chest x‐ray over a 3‐year period.5 More recently, the 
Dutch‐Belgium Lung Cancer Screening [NELSON] Trial also found 
decreased lung cancer mortality in high‐risk individuals screened 
with LDCT of the chest compared to chest radiography.6 In 2013, 
the NLST results led to the Grade B recommendation from the US 
Preventive Services Task Force of lung cancer screening with LDCT 
for high‐risk individuals (aged 55‐80 years with a minimum 30 pack‐
year smoking history who are current or former smokers who quit 
within the past 15 years).7 Subsequently, the Centers for Medicare 
and Medicaid Services issued a coverage determination to cover 
lung cancer screening among high‐risk individuals with an upper age 
limit of 77.8
Although new screening programmes with LDCT have been im‐
plemented throughout the United States, screening uptake remains 
low9 and persons' decisions to screen or not screen for lung cancer 
remain poorly understood.10‐12 The purpose of this study was to de‐
scribe how current and long‐term smokers explain their decisions to 
participate or not in screening for lung cancer with LCDT.
2  | PARENT STUDY: IDENTIF YING 
FAC TORS A SSOCIATED WITH LUNG 
C ANCER SCREENING
Data for this study were collected as part of a larger sequential ex‐
planatory mixed methods study designed to identify factors associ‐
ated with lung cancer screening (referred to as the parent study). 
The study consisted of Phase 1, a quantitative phase, and Phase II, a 
qualitative phase. Both phases of the parent study were approved by 
the authors' institutional review board, and all research team mem‐
bers had human subjects training. Although Phase II is the focus of 
this report, Phase 1 is first briefly described as it provided the con‐
text of Phase II.
2.1 | Phase I: quantitative study
The aim of Phase I was to test an explanatory framework for lung 
cancer screening participation. As seen in Figure 1, the antecedent 
variables are psychological variables, demographic and health status 
characteristics, cognitive variables, health‐care provider recommen‐
dations (y/n), and social and environmental variables. The mediating 
variables are lung cancer screening health beliefs, and the outcome 
variable is lung cancer screening participation (y/n).
A 88‐item self‐report web‐based survey was developed to 
measure each of the variables in the model. To measure lung can‐
cer screening participation, participants were asked if they had a 
F I G U R E  1   Conceptual model for lung 
cancer screening participation
Demographic & Health 
Status Characteristics 
(age, sex, race/ethnicity, 
education, income, 
insurance status, 
smoking status, family 
history of lung cancer)
Social & 
Environmental 
Variables (social 
influence, media 
exposure) 
Health-Care Provider 
Recommendation 
                 Antecedents                Mediators                 Outcome 
Lung Cancer 
Screening Health 
Beliefs (perceived 
risk, perceived 
benefits, perceived 
barriers, self-efficacy) 
Lung Cancer 
Screening 
Participation: Low 
-Dose Computed 
Tomography Verified
Stage of Adoption for 
Lung Cancer 
Screening 
Psychological 
Variables (perceived 
smoking-related stigma, 
medical mistrust, cancer 
fatalism, lung cancer 
worry, lung cancer fear, 
anxiety) 
Knowledge  
(lung cancer and 
screening)  
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LDCT scan in the past 12 months to screen for lung cancer. They 
were given a description of LDCT of the chest and provided a pho‐
tograph of the scanner so as to distinguish the procedure from a 
chest x‐ray.
A purposive sample of 515 long‐term current and former smok‐
ers in the United States who were eligible for lung cancer screening 
per USPSTF guidelines were recruited via a nationwide Facebook 
targeted advertisement. Facebook has the ability to ‘target’ an ad‐
vertisement by demographics and keywords listed in each individual 
Facebook user's profile or interest list, which allowed us to purpo‐
sively sample people who were age 55 years and older and indicated 
smoking as an interest.
Data were collected using REDCap, a secure web‐based plat‐
form. Interested persons completed a screening questionnaire and, if 
eligible, saw a message that invited them to participate in the study. 
Embedded in the message was an informed consent document that 
could be signed electronically. More information about Phase I is 
presented elsewhere (under review).
2.2 | Phase II: qualitative study
Phase II was a qualitative study in which telephone interviews were 
conducted with a sub‐set of the participants in Phase I. Participants 
in Phase II were asked to explain and expand on some of their re‐
sponses to items in the Phase I survey.
2.3 | Research team and training
Phase II was conducted by three senior nurses researchers, a clini‐
cal research project manager and six baccalaureate nursing students 
in an honours programme. The senior researchers included two 
nurses with expertise in cancer prevention and one with expertise in 
qualitative methods. The nursing students and the project manager 
conducted the interviews and did initial coding on the transcripts 
and the senior researchers further analysed the data to address the 
study aim.
The qualitative methods expert provided a series of training ses‐
sions on qualitative interviewing and basic coding techniques. The 
training consisted of presentations on qualitative interviewing and 
coding strategies, role playing exercises to develop interviewing 
skills, and practice coding sessions. The qualitative expert also re‐
viewed all of the taped interviews and provided ongoing feedback as 
the interviews were conducted.
2.4 | Sampling and recruitment
Participants who completed the survey were asked if they would be 
willing to participate in a follow‐up phone call and 336 expressed a 
willingness to do so. Selective sampling was used to recruit a sub‐
sample of 40 persons from those who agreed to participate in the 
telephone interviews. Phase II sampling procedures were aimed at 
ensuring participants whose screening decisions converged with, or 
diverged from, the Phase I explanatory framework in a variety of 
ways were interviewed. Therefore, we selected 20 participants who 
had screened and 20 who had not. Within each group, we included 
10 persons whose scores on the psychological and cognitive/health 
belief measures were hypothesized to be favourable to screening 
and 10 persons whose scores on these measures were hypothesized 
to be unfavourable to screening. The creation of the profiles and 
the selective sampling of participants is described in more detail in 
Appendix S1. Those who were selected were contacted by email or 
phone and scheduled for a phone interview.
2.5 | Data collection
Tailored semi‐structured interview guides were developed for each 
participant in Phase II based upon whether they had screened or 
not combined with their scores on the psychological and/or cogni‐
tive and health belief factors subscales in Phase I (see Appendix S2). 
The first question on the survey in Phase I was whether participants 
had a LDCT to screen for lung cancer in the past 12 months. During 
the interview, the interviewer confirmed their response. If the par‐
ticipant had screened, they were asked how they had decided to 
be screened. If they had not screened, they were asked how they 
decided not to screen. The interviewers then referred to the par‐
ticipants' high or low results on the subscales and asked participants 
to elaborate on their responses. For example, if a participant had 
scored low on the medical mistrust subscale, they would be asked to 
describe interactions with providers that lead to mistrust.
The interviews lasted between 15 and 60 minutes. While some 
participants were reticent and difficult to engage, most were forth‐
coming with their thoughts and feelings about lung cancer screen‐
ing. The interviews were digitally recorded and transcribed verbatim 
by a member of the research team. Each transcript was given an 
identification number (001‐040), and no identifying data were in‐
cluded on the transcripts.
2.6 | Data analysis
Data were analysed using conventional content analysis.13 
Conventional content analysis is an inductive process that allows 
codes and categories to emerge from the data rather than a deduc‐
tive process confirming or refining a pre‐existing theoretical struc‐
ture.13 To address the research aim, we focused primarily on the 
participants' direct responses to the interviewer's initial query about 
why they had chosen to be screened for lung cancer or not. While 
later questioning sometimes provoked more reflective responses 
about decisions to screen (eg Did your experience with stigma influ‐
ence your decision to screen?), we determined that it was important to 
first examine participants' spontaneous unprompted explanations of 
their screening decisions. If, however, participant responses to later 
questions provided additional clarity about their stated reasons for 
their screening decisions, these data were brought to bear on the 
analysis as well.
The nursing students and the project manager were each as‐
signed transcripts to code individually. All data relevant to the 
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participants' stated reasons for being screened or not were ex‐
tracted and divided into text units (eg words, phrases, sentences or 
short passages capturing a single thought). They labelled each text 
unit with a short code that captured its essence. A senior researcher 
verified each of the codes by re‐examining the transcripts.
The codes were then entered into data display tables.14 The ta‐
bles were constructed by assigning a row to each participant and 
labelling it with their study ID number. The table had two columns—
one displayed each participant's basic demographic information, 
including their age, gender, ethnicity and smoking status, and one 
displayed all the codes associated with that participant. The rows 
were initially divided into two groups according to whether the par‐
ticipant had been screened or not.
The senior researchers met to summarize the information on 
the data display tables using a process of discussion and consensus. 
Because the analysis involved a low level of interpretation, analytic 
disagreements were few and easily resolved by a re‐examination of 
the data. When examining the interview responses for those who 
had not been screened, we recognized that they were a heteroge‐
neous group in terms of their screening decisions, which ranged 
from having made a firm decision not to be screened to having made 
a firm decision to be screened. We therefore divided the sample into 
five groups: persons who had decided not to be screened (Group 1), 
persons who had not deliberately considered being screened but 
were at least somewhat open to it (Group 2), persons who had de‐
liberately considered being screened but had not made a definitive 
decision (Group 3), persons who fully intended to be screened but 
had yet to do so (Group 4) and persons who had been screened at 
the time of the interview (Group 5).
The codes associated with each group were compared for sim‐
ilarities and differences and grouped into categories. The catego‐
ries, which represented a variety of reasons that participants in each 
group decided to be screened or not, were validated with a re‐exam‐
ination of the transcripts. The research team determined that the 40 
interviews yielded ample data to provide a robust description of how 
current and long‐term smokers explain their decisions to participate 
or not in screening for lung cancer with LCDT. A narrative descrip‐
tion of each category was prepared and reviewed by the research 
team.
3  | RESULTS
3.1 | Sample
Forty persons participated in the interviews, but data from one per‐
son were lost due to recording equipment failure. One participant 
had indicated on her survey that she had screened but denied this 
during the interview and was therefore considered a non‐screener 
for this analysis. No participants reported having a lung scan be‐
tween the survey and the interview. The final sample thus included 
39 participants: 18 persons who had screened and 21 persons who 
had not screened. Participants hailed from 20 states representing all 
geographical regions of the United States.
Of the final sample of 39, 26 were women and 13 were men. 
Participants ranged in age from 55 to 70, with an average age of 
62 years. Thirty‐five were Caucasian, one was African American, 
one was American Indian/Alaskan Native, and two were mixed 
race (ie African American and Native Hawaiian, Caucasian and 
American Indian). Twelve were divorced, 10 were married, seven 
were never married, five were living with a partner, and five were 
widowed. Twenty‐eight were not working for pay, six were working 
full‐time, and five were working part‐time. Eleven had graduated 
from college, 21 had completed some college, six had graduated 
from high school, and one had not graduated from high school. 
Eight had an annual income of >$50k, 18 between $25K and $50k, 
and 13 < $25k. Twenty‐one participants were former smokers and 
18 currently smoked. Information about earlier screening experi‐
ences other than the LDCT or illness history was not collected in 
the Phase I survey.
3.2 | Decisions regarding participating in lung 
cancer screening
In response to the interviewers' initial questions about decisions re‐
garding lung cancer screening participation, most participants pro‐
vided clear reasons why they had screened or alternatively why they 
had not. The reasons each of the five groups, identified above, pro‐
vided for their screening decisions are described below. The descrip‐
tion of the groups are ordered from those most resistant to being 
screened (Group 1) to those who had been screened (Group 5). For 
each verbatim quote, the participant's study identification number 
(ID) is included in parentheses.
3.2.1 | Group 1: no intention to be screened
Some participants had no intention to be screened because they felt 
it was unnecessary. Most of these participants were fairly adamant 
that a lung scan would be a ‘waste of time’, ‘not worth the time or 
effort’ or a needless expense. They indicated that their physician 
either had not mentioned a lung scan or recommended against it. 
A 65‐year‐old man who currently smoked (ID: 018) stated, ‘I firmly 
believe that if he [his physician] felt it [the lung scan] was necessary, 
he would have recommended it’.
Several participants thought a lung scan was unnecessary be‐
cause they did not have symptoms associated with lung cancer. A 57‐
year‐old woman who currently smoked (ID: 032) said, ‘I don't have 
any symptoms or any reason to go [get a lung scan…]’. This partici‐
pant and others assumed they would surely have symptoms if they 
had lung cancer.
Others were convinced that a lung scan was redundant if they 
had had chest x‐rays or if their physician routinely ‘listened to’ their 
heart and lungs. A 68‐year‐old man who formerly smoked and was 
an x‐ray technologist (ID: 012) said, ‘I feel if a chest x‐ray doesn't 
show it, what good is a CT? If you're going to get it [lung cancer], 
it's going to show up on a chest x‐ray eventually, so to waste some‐
body's time when someone else needs a CT…’
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3.2.2 | Group 2: no deliberate consideration but 
somewhat open to being screened
Some participants who had not had a lung scan had not deliber‐
ately considered being screened. These participants, unlike those 
in Group 1, did not maintain it was unnecessary but they had not 
thought much about it. A 58‐year‐old woman who currently smoked 
(ID: 034) said, ‘I just never considered it. I've always been pretty 
healthy…’
Like Group 1, participants in Group 2 indicated that their phy‐
sicians had not discussed screening. Moreover, participants in this 
group knew little about lung scans. A 55‐year‐old woman who for‐
merly smoked (ID: 015) said, ‘If you had knowledge of exactly what it 
[lung scan] is … I think more people would have it done’.
Unlike participants in Group 1, however, those in Group 2 ex‐
pressed some openness to being screened, although their com‐
mitment was typically tepid. Some indicated they would consider 
having a lung scan under certain conditions, such as if a physi‐
cian recommended it or if they started to feel badly or develop 
symptoms. A 62‐year‐old woman who formerly smoked (ID: 027) 
said, ‘Yes, that's [screening] a possibility because maybe if I was 
going to the same person [provider] all of the time and I had been 
recommended on maybe more than one occasion I might consider 
doing it’.
3.2.3 | Group 3: deliberate consideration but no 
definitive decision to be screened
Some participants who had not had a lung scan had considered being 
screened in an intentional way. Unlike Group 2, they were familiar 
with lung scans and having one had been on their minds. A 55‐year‐
old woman who formerly smoked (ID: 020) said, ‘I thought about it 
many times…’
Participants in Group 3 revealed a number of reasons why they 
had not been screened. Like Groups 1 and 2, they indicated that their 
physicians had not recommended a lung scan. A 70‐year‐old woman 
who currently smoked (ID: 008) said, ‘It [lung scan] hadn't been rec‐
ommended to me, [but] I've thought about it’. For some, the decision 
to get a lung scan hinged on their physician's recommendation. The 
55‐year‐old woman mentioned above (ID: 020) who had thought of 
having a lung scan many times said that she would ‘absolutely want’ 
a scan if her physician recommended it to her.
A few participants in this group stated they had not had the time 
to get screened, whereas others were deterred by a variety of other 
factors. The cost of the scan was a concern for some of the partic‐
ipants who said they would have the scan if it was free or covered 
by insurance. Other participants wanted to be screened but were 
reluctant to get a scan because they feared the results. A 55‐year‐
old woman who formerly smoked (ID: 014) said, ‘I am going to go 
[to get a lung scan] but right now I haven't gone. Eventually I will go. 
I'm trying to work up the courage’. Other reasons participants put 
off screening included having other more pressing health issues and 
having a serious ill family member who required their attention.
3.2.4 | Group 4: intention to be screened
Unlike the participants in Groups 3 who considered a lung scan but 
had not decided definitively to have one, participants in Group 4 had 
made a fairly firm decision to be screened. These participants indi‐
cated that they had planned to get screened and were committed to 
following through. A 55‐year‐old woman who formerly smoked (ID: 
017) said, ‘Yes, I have considered it [having a lung scan] being that I 
do have COPD and I have been a smoker for over 40 years. So, yes, I 
plan on being screened as soon as possible’.
These participants discussed why they delayed getting a lung 
scan in light of the fact that they were determined to be screened. 
In some instances, participants were hindered by a physician who 
was not supportive of the lung scan. A 62‐year‐old woman who 
formerly smoked (ID: 017) decided to have a lung scan done ‘as a 
baseline’ and went to ‘the x‐ray place’ to have it done. However, 
she was told to get a ‘written order’ from her physician for the scan. 
The participant indicated that her physician refused to provide 
the order because he believed the scan was unnecessary as she 
was asymptomatic. A 63‐year‐old woman who currently smoked 
(ID: 021) had decided to have a lung scan, along with a number of 
other screening procedures, when she received Medicare in a few 
months following the interview.
3.2.5 | Group 5: had been screened
All persons who had had a lung scan at the time of the interview 
clearly articulated at least one reason why they chose to be screened 
and several provided more than one reason. The most common rea‐
sons included experiencing pulmonary problems, receiving a recom‐
mendation from a physician and valuing early detection.
Experiencing pulmonary problems
Some participants indicated that they had a lung scan because they 
had a pulmonary illness such as chronic obstructive pulmonary dis‐
ease (COPD), emphysema, collapsed lung, pulmonary hypertension, 
or scleroderma or were experiencing ‘breathing problems’, shortness 
of breath or a cough. A 64‐year‐old woman who formerly smoked 
(ID: 001) said, ‘I was screened because I do have Stage 4 COPD, so of 
course they did test for cancer’. Some of these participants indicated 
that the scan was a necessity rather than a choice.
Receiving a recommendation from a physician
Some participants indicated that they had been screened on the 
recommendation of their physician. Some physicians had recom‐
mended the scan because the participant was having some pulmo‐
nary problems as described above, but others recommended it in 
the absence of known problems due to the participants' smoking 
history. Participants typically did not question the advisability of 
a lung scan when recommended by their physicians. A 69‐year‐old 
woman who currently smoked (ID: 023) said, ‘My doctor suggested 
it. Of course, being a smoker I said, well, that's a good idea. I had no 
problem with it…’
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Valuing early detection
Some participants indicated that they had a lung scan because they 
valued preventing or detecting medical problems early. They indi‐
cated that they had a lung scan because they wanted to ‘stay on top 
of [my] health’, felt ‘early detection is best’ and ‘wanted to catch it 
[cancer] early’. Some compared the advisability of having a lung scan 
to that of other routine screening procedures such as mammography 
or colonoscopy. A 64‐year‐old woman who formerly smoked (ID: 
001) said, ‘I try to stay on top of various medical issues, just so that if 
there is something going on, I can catch it as early as possible’. Some 
of these participants, rather than their health‐care providers, initi‐
ated the lung scan. A 56‐year‐old man who formerly smoked (ID: 024) 
learned about the lung scan because his hospital was running a ‘spe‐
cial’ that was widely advertised. He said, ‘I decided to get screened on 
my own and when I was talking to one of my doctors about it, they 
said it was a great idea. So I went ahead and did it’.
Other reasons
A few participants cited other reasons for having a lung scan. Some 
indicated that they had a lung scan because it was covered by their 
insurance as a ‘preventative tool’. Others indicated they had a lung 
scan because it was required by Medicaid or was part of a research 
study. One had a scan because of a family history of lung disease.
4  | DISCUSSION
Consistent with our prior work,12 participants' decisions to screen 
for lung cancer ranged from a firm decision not to screen because 
they believed it was unnecessary and a waste of time to a decision 
to screen based on a firm conviction that screening was essential to 
their health and well‐being. Factors that were most likely to promote 
screening included perceived physician endorsement and experienc‐
ing pulmonary symptoms. Factors that impeded decisions to screen 
included the belief that other tests detect cancer, cost of the scan, 
fear of the results and other life stressors.
As a result of the findings, the team determine that the groups 
identified in this analysis aligned with precaution adoption process 
model (PAPM)15 and each group could be placed to be in one of the 
stages outlined in the model. The PAPM focuses on how people 
make decisions to take action or not regarding health issues and how 
they translate these decisions into actions. The seven stages in the 
model are as follows: stage 1: unaware of issue, stage 2: unengaged 
by issue, stage 3: undecided about acting, stage 4: decided not to 
act, stage 5: decided to act, stage 6: acting and stage 7: maintenance. 
People who are undecided about taking action (stage 3) can either 
stay in that stage or decide not to act (stage 4) or decide to act (stage 
5). No persons who participated in our interviews would have been 
in Stage 1 because all would have been aware of LDCT scans for lung 
cancer due to their participation in the study. However, participants 
in our Group 2 could be considered to be in Stage 2 of the PAPM 
as they were unengaged in thinking about screening. Participants 
in our Group 3 could be considered to be in Stage 3 of the PAPM 
because they were engaged in making a decision but undecided 
about whether or not to have a scan. Participants in our Group 1 
could be considered to be in Stage 4 of the PAPM as they had made 
a deliberate decision not to be screened. Participants in our Group 
4 could be considered to be in Stage 5 of the PAPM because they 
had decided to be screened, and participants in our Group 5 could 
be considered to in Stage 6 of the PAPM because they had followed 
through with screening. Because the recommendation for annual 
lung cancer screening with LDCT of the chest is fairly recent, no one 
in our sample had had a series of lung scans for maintenance, which 
defines Stage 7 of the PAPM.
Regardless of the current lung cancer screening status of partic‐
ipants, recommendations of physicians were paramount to the de‐
cision participants made about screening. Many indicated that they 
screened without hesitation on the advice of their physicians, whereas 
no participants went against the advice of physicians who had encour‐
aged them to be screened. Most commonly, participants who had not 
been screened indicated their physicians had not mentioned lung can‐
cer screening, had not strongly recommended it or had recommended 
against it. These findings are consistent with our previous studies that 
found that a provider recommendation is a strong predictor of lung 
cancer screening participation16‐18 and with studies on other types of 
cancer screening that found that a provider recommendation is the 
best predictor of breast and colorectal cancer screening.17,19‐21
The results also revealed that several participants held inaccurate 
beliefs that influenced their decisions about lung cancer screening 
participation. Our findings support similar research confirming lack of 
knowledge about the concept of screening.12,22,23 A common miscon‐
ception was that those with lung cancer are symptomatic and thus 
screening was unnecessary in the absence of symptoms. Another 
misconception was that routine examinations and chest x‐rays would 
reveal lung cancer thereby rendering a LDCT redundant. These two 
misconceptions discouraged screening and thus could impede detec‐
tion of lung cancer at early, more treatable stages. Moreover, several 
participants were convinced that lung cancer screening would be 
very expensive and not covered by insurance. Although this concern 
was found in with our prior studies examining screening barriers,16,17 
lung cancer screening is a Grade B recommendation by the USPSTF 
with zero copayment for Medicare beneficiaries.
5  | LIMITATIONS
The findings should be considered in the context of several study 
limitations. Determination of screening status was based on self‐
report, and a few participants needed to be reminded a lung scan 
was different than a chest x‐ray. However, all participants had been 
provided a picture of a LDCT scan as well as a description of the 
scan and its purpose. Another limitation was that prior participation 
in Phase I may have influenced the findings of Phase II. Some par‐
ticipants may have discussed a willingness or intent to screen dur‐
ing their interviews because the survey had implied that screening 
was important. Moreover, some may have engaged in behaviours 
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following the survey that they might not have otherwise, such as 
learning more about screening or discussing screening with family, 
friends, or their health‐care providers. However, during the inter‐
views, no participants revealed that the survey influenced their sub‐
sequent behaviours or their decisions about screening.
Facebook recruitment may have also limited the findings. While 
69% of the adult population use Facebook,24 it is unclear if they dif‐
fer from adults who do not use Facebook in ways that might influ‐
ence screening decisions (eg more exposure to information about 
the health hazards of smoking or the availability of LDCT).
Another study limitation was the lack of ethnic diversity in the 
sample. Only four participants (10% of the sample) were from mi‐
nority groups. This may have stemmed from the well‐documented 
phenomenon that minority persons, especially African Americans, 
are less likely participate in research due to mistrust.25,26 Our re‐
cruitment methods might have also contributed to the lack of diver‐
sity. While the proportion of White and Black adults in the United 
States who use Facebook is equal (70% for both groups),24 some 
methodologists have suggested that targeted paid advertisements 
are not always successful in encouraging all groups to engage in re‐
search and the use of other strategies, such as direct communication 
with existing Facebook groups that address issues of importance to 
the minority group to be recruited and networking with page ad‐
ministrators who can promote the study, may be needed.27 We also 
recognize that there were twice as many women as men in the quali‐
tative sample and this could have had an impact on results. However, 
our prior work on the role of gender in lung cancer screening be‐
haviour has not revealed any gender‐related differences.28
In addition, in Phase I, we did not collect data on some factors 
that might have influenced screening decisions, such as prior cancer 
screening and prior cancer experiences, and this information could 
have added to the Phase II analysis. Moreover, our analysis did not 
allow us make definitive conclusions about whether persons who 
were current or former smokers differed in their reasons to screen or 
not. However, there was no manifest indication that smoking status 
influenced decisions to screen. For example, former smokers did not 
indicate they avoided screening because they were not at risk for lung 
cancer and current smokers did not indicate they avoided screening 
because the results might be a cause for them to stop smoking. In 
addition, because our interviews occurred at a single time point, 
we could place participants in one of the five groups but could not 
account for dynamic changes in screening over time, such as those 
outlined in the PAPM15 model. For example, we recognize that be‐
havioural intentions are not the same as actual behaviour change29 
and our findings do not explain how participants move from intending 
to screen to actually getting screened.
To address the limitations of this study, we suggest a study in 
which screening‐eligible persons are interviewed at several time 
points to capture the dynamic unfolding of screening participation. 
We also recommend recruiting an ethnically diverse sample and ex‐
ploring the influence of a number of factors, such as smoking status 
and sociodemographic background, on screening decisions. For ex‐
ample, while determining the effects of demographic factors, such 
as age, gender, race and income, on screening decisions was beyond 
the scope of this study, future research with larger and more diverse 
samples could explore such influences.
6  | CLINIC AL IMPLIC ATIONS
Our study confirms that education regarding lung cancer screening 
should target both patients and providers and should be widely imple‐
mented. Similar to findings by Raz and colleagues,30 our findings sug‐
gest that such efforts should clarify the difference between screening 
for lung cancer to detect it early in the absence of symptoms and 
diagnostic testing to identify aetiology when symptoms are present. 
Education initiatives should stress that LDCT is the only effective and 
approved test to screen for lung cancer and dispel the misconception 
that a chest x‐ray is an effective screening test. Moreover, all provid‐
ers need to be aware of national guidelines and practice recommenda‐
tions and the evidence that supports screening with LDCT. Targeted 
provider education should be offered through multiple venues (ie pro‐
fessional organizations, public service announcements, clinical pearls 
[tips for clinicians to apply in clinical practice], continuing education 
offerings). Our findings also suggest that high‐quality patient‐provider 
communication about lung cancer screening should occur regularly. 
Given that our participants' reasons for not screening were varied and 
in some instances evolving, opportunities to discuss their hesitancy to 
screen with a provider would likely improve screening rates.
7  | SUMMARY
During phone interviews, screening‐eligible persons were asked 
to explain their decisions about participation in screening with 
LDCT. Some revealed they decided to screen because they were 
firmly convinced of its benefit, some revealed they decided not 
to screen because they were certain it was unnecessary, and oth‐
ers discussed being open to screening, thinking about screening 
or intending to screen. Although a variety of factors influenced 
their decisions, including several misconceptions about LDCT, 
their health‐care providers' role in discussing or endorsing screen‐
ing was paramount. The findings indicate that education regarding 
lung cancer screening is needed for screening‐eligible persons and 
their providers and that high‐quality patient‐provider communica‐
tion regarding screening is most likely to improve screening rates.
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